AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Adagene's Price Target Adjusted Down to $7.00 by HC Wainwright Amidst Analyst Ratings
ByAinvest
Sunday, Aug 17, 2025 12:43 pm ET1min read
Adagene (ADAG) analyst ratings maintain 'Buy' with a price target adjusted from $8.00 to $7.00 USD, a 12.50% decrease. HC Wainwright & Co. analyst Arthur He made this revision, and the average target price for ADAG is $9.64 with a high estimate of $21.07 and a low estimate of $3.50. The average target implies an upside of 379.73% from the current price of $2.01.
Adagene Inc. (NASDAQ: ADAG) has seen a revision in its analyst ratings, with HC Wainwright & Co. analyst Arthur He lowering the price target from $8.00 to $7.00 USD. Despite this adjustment, the stock maintains a "buy" rating, indicating a potential upside of 248.26% based on the current price of $2.01 [1].The revised price target reflects a 12.50% decrease, aligning with recent regulatory milestones and strategic partnerships. Adagene's recent FDA meeting provided clarity on the development path for its lead program, muzastotug (ADG126), which is now in Phase 2 trials in combination with pembrolizumab for microsatellite stable colorectal cancer (MSS-CRC) patients [2].
The average target price for ADAG is $9.64, with a high estimate of $21.07 and a low estimate of $3.50. This average target implies an upside of 379.73% from the current price of $2.01. Other analysts have also shown interest in ADAG, with Leerink Partners initiating coverage with an "outperform" rating and a $7.00 price target [1].
Investors should consider the recent developments, including strategic partnerships and clinical trial advancements, when evaluating Adagene's potential. The company's debt-to-equity ratio of 0.01 and strong liquidity ratios (current ratio of 2.29, quick ratio of 2.30) indicate a solid financial position [1].
References:
[1] https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-adagene-nasdaqadag-stock-price-2025-08-15/
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-lowers-adagene-stock-price-target-to-7-on-development-path-clarity-93CH-4195188
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet